NCT06234137View on ClinicalTrials.gov

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

November 27, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

August 1, 2031

Conditions
Breast Neoplasm Female
Interventions
DRUG

Docetaxel

75mg/m2 iv escalating to 100mg/m2 iv 3-weekly

DRUG

Carboplatin

AUC=6 min/mL iv 3-weekly

DRUG

Inetetamab

8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly

DRUG

Pyrotinib

400mg orally daily

Trial Locations (1)

325000

RECRUITING

the First Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Wang Ouchen

OTHER